Gastric bypass is the most clinically and cost-effective form of interventional surgery for people living with severe obesity ...

Arguably the most pressing question facing clinicians and patients today is not “which treatment works?” but “which treatment ...

Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.

GLP-1 medications are reshaping the weight management landscape — and beginning to take a bite out of bariatric surgery volumes in hospitals. Between 2022 and 2023, bariatric surgery rates fell 25.6% ...

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Obesity is a growing global epidemic and a major risk factor for cardiovascular disease. However, previous weight loss interventions have largely failed to demonstrate consistent cardiovascular ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...